GlobeNewswire by notified

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 Scientific Congress & Expo


-Finalresults from pilot study of linzagolix for the treatment of severe adenomyosisto be presented in a second poster -

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

GENEVA, Switzerland October 20, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of clinical data from PRIMROSE (1 and 2) Phase 3 study of linzagolix for the treatment of uterine fibroids as well as final data from a pilot study of linzagolix for the treatment of severe adenomyosis at the American Society for Reproductive Medicine (ASRM) 2021 Scientific Congress & Expo, being held October 17-20, 2021.

“Enlarged uterine volume is an important driver of abnormal bleeding and pain associated with uterine fibroids; moreover, bulk and pressure symptoms may strongly impact women’s quality of life,” said Jacques Donnez, M.D., Ph.D., a key opinion leader in gynecologic therapeutics. “We are encouraged by the positive data and the robust responses that were observed at the full suppression dose of linzagolix, demonstrating the potential to promote meaningful reductions in uterine volume in addition to reduction in heavy menstrual bleeding. Linzagolix is the only GnRH antagonist to provide flexible dosing options to better address the individual needs of patients, and these results further underscore its differentiated profile and potential clinical utility.”

Linzagolix for the Treatment of Uterine Fibroids

The abstract, titled “Administration of Hormonal Add-Back Therapy (ABT) Counteracts the Uterine Volume Reducing Effects of Oral GnRH Antagonist Therapy,” is presented by Dr. Donnez in an ePoster and available on-demand through the ASRM conference portal.

PRIMROSE 1 & 2 were randomized, parallel group, double-blind, placebo-controlled Phase 3 studies that investigated the efficacy and safety of two dosing regimens of linzagolix, 100 mg or 200 mg once daily, alone or in combination with hormonal ABT (1 mg estradiol and 0.5 mg norethisterone acetate) for the treatment of heavy menstrual bleeding associated with uterine fibroids. PRIMROSE 1 was conducted in the United States and enrolled 574 women. PRIMROSE 2 was conducted in Europe and the United States and enrolled 535 women. Both trials comprised a 52-week treatment period. Women receiving linzagolix 200 mg alone or placebo were switched to linzagolix 200 mg + ABT after 24 weeks, except for a group of placebo subjects in one study who continued placebo until 52 weeks. Uterine volumes were measured using transvaginal ultrasound at baseline, 24 and 52 weeks. Change from baseline was analyzed using a mixed model with repeated measures. Serum estradiol (E2) levels were measured using a validated sensitive assay.

Summary of the data

Key takeaway: Once daily treatment of 200 mg linzagolix without ABT reduced uterine volume by 39% after 24 weeks. However, co-administration of hormonal ABT after 24 weeks counteracted the uterine volume reducing effects at 52 weeks.

In women who received linzagolix without ABT for 24 weeks and then changed to linzagolix 200 mg with ABT from 24 to 52 weeks:

  • Uterine volume at 24 weeks: Mean ratio to baseline was 0.61 (95% CI 0.57, 0.65) corresponding to a 39% reduction
  • Fibroid volume at 24 weeks: Mean ratio to baseline was 0.51 (95% CI 0.44, 0.58) corresponding to a 49% reduction
  • Estradiol levels at 24 weeks: Median serum E2 was suppressed to 9 pg/mL
  • Uterine volume at 52 weeks: Mean ratio to baseline increased to 0.79 (95% CI 0.73, 0.86) corresponding to a 21% reduction from baseline.
  • Estradiol levels at 52 weeks: Median serum E2 increased to 43 pg/mL

To view this piece of content from, please give your consent at the top of this page.

To view this piece of content from, please give your consent at the top of this page.

Linzagolix for the Treatment of Severe Adenomyosis

The abstract, titled “Efficacy and Safety of Linzagolix for the Treatment of Severe Adenomyosis: Final Results from a Pilot Study,” is presented by Dr. Donnez in an ePoster and available on-demand through the ASRM conference portal.

This single-center, open-label, exploratory study was designed to assess the efficacy and safety of linzagolix in the treatment of symptomatic adenomyosis. Premenopausal patients with MRI-confirmed adenomyosis, moderate-to-severe pain and abnormal uterine bleeding were treated with high-dose linzagolix (200 mg) for 12 weeks followed by low-dose (100 mg) for an additional 12 weeks. The primary measure of efficacy was the reduction in uterine volume assessed by MRI. Other endpoints included pelvic pain, bone mineral density (BMD) and quality of life.

Summary of the data

Key takeaway: A high dose of 200 mg linzagolix reduced uterine volume by 55% from baseline at 12 weeks and 32% from baseline at 24 weeks after continued treatment with 100 mg linzagolix. Pelvic pain was markedly reduced at 12 and 24 weeks with initial signs of reduction after 4 weeks. Overall, significant improvements in quality of life were reported.

  • Estradiol levels: Median serum estradiol was suppressed to 12 pg/mL after four weeks and maintained up to 12 weeks. Median serum estradiol was partially suppressed (19 to 38 pg/mL) from 16 to 24 weeks.
  • Uterine volume: Mean uterine volume decreased significantly and was 198 cm3 (p<0.0001) after 12 weeks and 139 cm3 (p<0.006) at 24 weeks, corresponding to a 55% reduction from baseline at 12 weeks and an additional 32% reduction from baseline at 24 weeks.
  • Pelvic pain: Mean pelvic pain score (0-10 numeric rating scale) was reduced from 8.4 at baseline to 3.4 (p=0.034) at 4 weeks with continued decrease from baseline of 6.0 (p=0.0035) at 12 weeks and 7.8 (p<0.0001) at 24 weeks.
  • Safety and tolerability: Hot flash and fatigue were the most common side effects. No serious adverse effects were reported.
  • BMD: Bone mineral density was assessed at 24 weeks and the mean ± SD % decrease at the lumbar spine was 2.4 ± 3.6% and the mean z-score was -0.65 (range -1.6, 0.9). This was consistent with effects of estradiol suppression on BMD.
  • Quality of Life: Significant improvements were observed in all of the EHP-30 domains at 12 and 24 weeks (p<0.05).

About Linzagolix
Linzagolix is a novel, once daily, oral GnRH receptor antagonist with a potentially best-in-class profile1,2,3. Linzagolix has completed clinical trial development for the treatment of heavy menstrual bleeding associated with uterine fibroids and is currently in late-stage clinical development for the treatment of pain associated with endometriosis. ObsEva licensed linzagolix from Kissei in late 2015 and retains worldwide commercial rights, excluding Asia, for the product. Linzagolix is not currently approved anywhere in the world.

About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit

Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of and commercialization plans for ObsEva’s product candidates, including linzagolix, expectations regarding regulatory and development milestones, including the potential timing of regulatory submissions to the EMA and FDA and ObsEva’s ability to obtain and maintain regulatory approvals for its product candidates, and the results of interactions with regulatory authorities. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, the impact of the ongoing novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2020 filed with Securities and Exchange Commission (SEC) on March 5, 2021 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:
CEO Office contact
Shauna Dillon
+41 22 552 1550

Investor Contact
Joyce Allaire
+1 (617) 435-6602

1. Stewart E, ASRM 2020; Late-breaker abstract P-930
2. Al-Hendy A, NEJM 2021; 384:630-42
3. Schlaff W, NEJM 2020; 382:328-40
4. Bradley L, ASRM 2020; Late-breaker abstract P-931


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified


Bid date, 2021-11-30Auction date2021-11-30Settlement date2021-12-01Maturity Date2021-12-08Nominal amount570 billion SEKInterest rate, %0.00Bid times09.30-10.00 (CET/CEST) on the Bid dateConfirmation of bids to e-mailrbcert@riksbank.seThe lowest accepted bid volume1 million SEKThe highest accepted bid volume570 billion SEKAllocation Time10.15 (CET/CEST) on the Bid dateProjected minimum liquidity surplus during the term1140 billion SEKExpected excess liquidity at full allotment570 billion SEK Stockholm, 2021-11-30

Stratio raises $12M Series A to Scale AI-based Predictive Fleet Maintenance Platform using Real-time Augmented Intelligence30.11.2021 09:02:00 CET | Press release

Investment led by Forestay with participation from existing investor Crane Venture Partners to be used to further accelerate global expansion, increase R&D, boost product development, and double headcount by the end of 2022 LISBON, Portugal and LONDON, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Stratio, the world’s leading real-time predictive fleet maintenance platform, today announced a $12M Series A funding round to further accelerate its growth. The investment, led by Forestay Capital, the Deep Tech and SaaS Venture Capital arm of Waypoint Capital, with participation from existing investor Crane Venture Partners, will be used to further accelerate the company’s global expansion, increase its R&D, speed up overall time-to-market, and double its headcount by the end of 2022. Stratio already has its technology deployed in 5 of the top 10 transportation companies in the world and has enabled transportation for 1.3 billion people so far. The company’s Annual Recurring Revenue (ARR) has grown 270

Not intended for U.S. Media – Solvay announces results of its tender offer to purchase bonds for cash30.11.2021 08:32:08 CET | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA OR TO ANY U.S. PERSON OR IN OR INTO ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. Solvay SA continues its deleveraging through the early redemption of bonds due in 2022 Brussels, 30 November 2021 --- Solvay SA (the “Issuer”) today successfully closed the tender offer on its outstanding EUR 750 million 1.625% bonds due 2022, by acquiring €372.5 million of senior debt, marking another step in the strong deleveraging that commenced in 2019. As part of its G.R.O.W. strategy, Solvay has prioritised cash generation and, since January 2019, has generated €2.3 billion operationally, both from improving

Sampo plc’s share buybacks 29/11/202130.11.2021 08:30:00 CET | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 30/11/2021 at 08:30 am Sampo plc’s share buybacks 29/11/2021 On 29/11/2021 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)33,86443.34AQEU34,08143.27CEUX4,67243.25TQEX109,28243.26XHELTOTAL181,89943.28 *rounded to two decimals On 1 October 2021, Sampo announced a share buyback programme of up to a maximum of EUR 750 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 4 October 2021, is based on the authorization granted by Sampo's Annual General Meeting on 19 May 2021. After the disclosed transactions, the company owns in total 5,631,827 Sampo A shares representing 1.01 per cent of the total number of shares in Sampo plc. Detai

Aino Health AB (publ): Världsledande tillverkare väljer Aino Healths SaaS-lösning HealthManager30.11.2021 08:30:00 CET | Pressemelding

Stockholm 30 November, 2021. Ett världsledande tillverkningsföretag och global marknadsledare inom aggregat-, mineralbearbetnings- och metallraffineringsindustrin har valt att utöka användningen av Aino Healths SaaS-lösning HealthManager. Avtalet innehåller totalt 2 400 licenser, varav 1 300 är nya licenser. "Vi är mycket glada och stolta över att fortsätta och utöka en nyckelaktör inom tillverkningsindustrin som kund. Vi ser fram emot att tillsammans öka personalens välbefinnande och engagemang", säger Jyrki Eklund, VD Aino Health. HealthManager är Ainos egen SaaS-lösning som stödjer chefer med interna hälsorelaterade processer och frånvarohantering. Det erbjuder också rapporterings- och analysverktyg för att följa viktiga mätvärden relaterade till företagets hälsohantering. Målet med lösningen är att digitalisera arbetsförmågasprocesser och öka medarbetarnas engagemang. Om Aino Health (publ) Aino Health är den ledande leverantören av Software as a Service-lösningar inom Corporate Hea

Aino Health AB (publ): World leading manufacturer chooses Aino Health's SaaS-solution HealthManager30.11.2021 08:30:00 CET | Press release

Stockholm 30 November, 2021. A world leading manufacturing company and global market leader for sustainable technologies in the aggregates, minerals processing and metals refining industries, has chosen to extend the usage of Aino Health’s SaaS-solution HealthManager. The agreement contains a total of 2 400 licenses, out of which 1 300 are new licenses. ”We are very happy and proud to continue and extend a key player in the manufacturing industry as a customer. We look forward to together increase their personnel’s’ wellbeing and engagement”, says Jyrki Eklund, CEO Aino Health. HealthManager is Ainos own SaaS solution that supports managers with internal health-related processes and absence management. It also offers reporting and analytic tools to follow key metrics related to corporate health management. The goal of the solution is to digitalize working ability processes and to increase employee engagement. About Aino Health (publ) Aino Health is the leading supplier of Software as a

PCI Biotech and Immunicum Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments30.11.2021 08:00:00 CET | Press release

Oslo, Norway, November 30, 2021 - PCI Biotech Holding ASA (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via Photochemical Internalisation and Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, announced today an extension of their current collaboration. The companies jointly research the possibility to overcome current hurdles in cancer immunotherapy by introducing tumor independent immune targets into the tumor microenvironment, in combination with vaccination or adoptive immunotherapies. The so-called Tumor Independent Antigen concept, which has been invented by Immunicum, could benefit from PCI Biotech’s antigen delivery technologies based on Photochemical Internalisation. Following the encouraging results of the first set of in vitro experiments, during which the delivery protocol of the combination treatment has been optimized, the c